C.R. Bard Inc. (NYSE:BCR) Chairman Timothy M. Ring sold 92,293 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $227.81, for a total value of $21,025,268.33. Following the sale, the chairman now owns 145,876 shares of the company’s stock, valued at approximately $33,232,011.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
C.R. Bard Inc. (NYSE:BCR) opened at 221.58 on Wednesday. The firm has a market capitalization of $16.28 billion, a PE ratio of 51.53 and a beta of 0.50. The stock has a 50 day moving average price of $221.52 and a 200-day moving average price of $219.92. C.R. Bard Inc. has a one year low of $172.21 and a one year high of $239.43.
C.R. Bard (NYSE:BCR) last released its earnings results on Tuesday, July 26th. The company reported $2.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.07. The business had revenue of $931.50 million for the quarter, compared to the consensus estimate of $915.22 million. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. C.R. Bard’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.27 earnings per share. On average, equities analysts forecast that C.R. Bard Inc. will post $10.17 earnings per share for the current year.
Several analysts have recently issued reports on the company. Bank of America Corp. downgraded C.R. Bard from a “buy” rating to a “neutral” rating in a research note on Friday, July 8th. JPMorgan Chase & Co. upped their price target on C.R. Bard from $214.00 to $225.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 27th. Evercore ISI assumed coverage on C.R. Bard in a research note on Thursday, September 15th. They set a “buy” rating and a $235.00 price target for the company. Deutsche Bank AG upped their price target on C.R. Bard from $234.00 to $240.00 and gave the stock a “hold” rating in a research note on Wednesday, July 27th. Finally, BMO Capital Markets restated a “hold” rating and set a $240.00 target price on shares of C.R. Bard in a research note on Wednesday, July 27th. Thirteen equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. C.R. Bard currently has an average rating of “Hold” and a consensus target price of $233.00.
Several hedge funds have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC bought a new stake in C.R. Bard during the first quarter worth about $101,000. JPMorgan Chase & Co. increased its stake in C.R. Bard by 353.4% in the first quarter. JPMorgan Chase & Co. now owns 667,533 shares of the company’s stock worth $135,290,000 after buying an additional 520,319 shares in the last quarter. BlackRock Japan Co. Ltd increased its stake in C.R. Bard by 5.6% in the first quarter. BlackRock Japan Co. Ltd now owns 99,002 shares of the company’s stock worth $20,065,000 after buying an additional 5,269 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in C.R. Bard by 4.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,234,725 shares of the company’s stock worth $452,912,000 after buying an additional 98,144 shares in the last quarter. Finally, BlackRock Fund Advisors increased its stake in C.R. Bard by 8.5% in the first quarter. BlackRock Fund Advisors now owns 1,886,656 shares of the company’s stock worth $382,369,000 after buying an additional 147,571 shares in the last quarter. 87.90% of the stock is currently owned by institutional investors and hedge funds.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.